Advanced search
Publication Cover
Cytokines, Cellular & Molecular Therapy Volume 7, 2002 - Issue 4
Journal homepage
10
Views
25
CrossRef citations to date
0
Altmetric
Research Article

Increased IFN-? synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia

Jorg M Aswald Department of Medicine (Hematology/Oncology), Bone Marrow Transplantation Service, Department of Medicine Princess Margaret Hospital, University of Toronto Ontario Toronto
,
Jeffrey H Lipton Department of Medicine (Hematology/Oncology), Bone Marrow Transplantation Service, Department of Medicine Princess Margaret Hospital, University of Toronto Ontario Toronto
,
Sandra Aswald Institute of Medical Sciences University of Toronto Ontario
&
Hans A Messner Department of Medicine (Hematology/Oncology), Bone Marrow Transplantation Service, Department of Medicine Princess Margaret Hospital, University of Toronto Ontario Toronto
Pages 143-149 | Published online: 26 Sep 2009

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Dorina Ujvari, Alena Malyukova, Ana Zovko, Elham Yektaei-Karin, Harsha S Madapura, Marton Keszei, Noemi Nagy, Kourosh Lotfi, Niclas Björn, Jonas Wallvik, Leif Stenke & Daniel Salamon. (2022) IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors. OncoImmunology 11:1.
Read now
John J. Powers, Jason A. Dubovsky, P. K. Epling-Burnette, Lynn Moscinski, Ling Zhang, Satu Mustjoki, Eduardo M. Sotomayor & Javier A. Pinilla-Ibarz. (2011) A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma 52:4, pages 668-679.
Read now

Articles from other publishers (23)

Yu-Cheng Chang, Yi-Hao Chiang, Kate Hsu, Chih-Kuang Chuang, Chen-Wei Kao, Yi-Fang Chang, Ming-Chih Chang, Ken-Hong Lim, Hung-I Cheng, Yen-Ning Hsu & Caleb G. Chen. (2021) Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Blood Cancer Journal 11:11.
Crossref
Deniz Goren Sahin, Klara Dalva, Sema Meriç, Günhan Gürman, Muhit Özcan, Önder Arslan & Mutlu Arat. (2019) İmatinib Tedavisi Alan Hastalarda T Lenfosit Aktivasyonunun Akım Sitometrik Analizi. OSMANGAZİ JOURNAL OF MEDICINE.
Crossref
Noriyoshi Iriyama, Hiromichi Takahashi, Katsuhiro Miura, Yoshihito Uchino, Masaru Nakagawa, Yoshihiro Hatta & Masami Takei. (2018) Enhanced perforin expression associated with dasatinib therapy in natural killer cells. Leukemia Research 68, pages 1-8.
Crossref
H S Madapura, N Nagy, D Ujvari, T Kallas, M C L Kröhnke, S Amu, M Björkholm, L Stenke, P K Mandal, J S McMurray, M Keszei, L S Westerberg, H Cheng, F Xue, G Klein, E Klein & D Salamon. (2017) Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells. Oncogene 36:32, pages 4619-4628.
Crossref
Qing Li, Zhaodong Zhong, Chen Zeng, Li Meng, Chunrui Li, Yi Luo, Hongxiang Wang, Weiming Li, Jue Wang, Fanjun Cheng, Anyuan Guo, Songya Liu, Caibao Jin, Xiaojian Zhu, Yong You & Ping Zou. (2016) A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. Oncotarget 7:36, pages 58234-58243.
Crossref
Laurence Zitvogel, Sylvie Rusakiewicz, Bertrand Routy, Maha Ayyoub & Guido Kroemer. (2016) Immunological off-target effects of imatinib. Nature Reviews Clinical Oncology 13:7, pages 431-446.
Crossref
A Kumar, N Roy Moulik, J Kishore, A Kumar & A Jain. (2015) Prolonged remission in a child with chronic myeloid leukemia following Parvo virus B19 (B19V) infection. Indian Journal of Medical Microbiology 33:3, pages 432-434.
Crossref
Stephanie M. TortorellaAndrew HungTom C. Karagiannis. (2015) The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia. Antioxidants & Redox Signaling 22:16, pages 1425-1462.
Crossref
Asmaa M. Zahran, Hosny Badrawy & Abeer Ibrahim. (2013) Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients. International Journal of Clinical Oncology 19:4, pages 753-760.
Crossref
Mark L. Ormiston, Yupu Deng, Natalie Rundle, Farid Bendjelloul, James N. Tsoporis, Thomas G. Parker, Duncan J. Stewart & David W. Courtman. (2013) A Lymphocyte-Dependent Mode of Action for Imatinib Mesylate in Experimental Pulmonary Hypertension. The American Journal of Pathology 182:5, pages 1541-1551.
Crossref
Peter Rohon. (2012) Biological therapy and the immune system in patients with chronic myeloid leukemia. International Journal of Hematology 96:1, pages 1-9.
Crossref
Helen Fernandes, Neil Fernandes, Siddharth Bhattacharya, Wen Chen, Anjali Seth, Meera Hameed, Neena Mirani & W Clark Lambert. (2010) Molecular Signatures Linked With Aggressive Behavior in Basal Cell Carcinoma: A Report of 6 Cases. The American Journal of Dermatopathology 32:6, pages 550-556.
Crossref
Bruno Robibaro, Anna Kropfmueller, Mathias Prokop, Paul Haber & Heinz Gisslinger. (2009) Imatinib, cytokines and interstitial lung disease in a patient with primary myelofibrosis. Annals of Hematology 89:8, pages 829-831.
Crossref
Shreya Kanodia, Eric Wieder, Sijie Lu, Moshe Talpaz, Gheath Alatrash, Karen Clise-Dwyer & Jeffrey J. Molldrem. (2010) PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal. PLoS ONE 5:7, pages e11770.
Crossref
Zuzana Humlová, Hana Klamová, Ivana Janatková, Karin Malíčková, Petra Králíková, Ivan Šterzl, Zdeněk Roth, Eva Hamšíková & Vladimír Vonka. (2010) Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment. Clinical and Developmental Immunology 2010, pages 1-17.
Crossref
Javier Pinilla-IbarzBijal ShahJason A. Dubovsky. (2009) The Biological Basis for Immunotherapy in Patients with Chronic Mye-logenous Leukemia. Cancer Control 16:2, pages 141-152.
Crossref
A-I Kälsch, M Soboletzki, W H Schmitt, F J van der Woude, A Hochhaus, B A Yard & R Birck. (2008) Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?. Clinical and Experimental Immunology 151:3, pages 391-398.
Crossref
Richard E. Clark. (2007) Immunotherapeutic strategies in chronic myeloid leukemia. Current Hematologic Malignancy Reports 2:2, pages 89-94.
Crossref
Jorg M. Aswald, Xing‐Hua Wang, Sandra Aswald, Andrzej Lutynski, Mark D. Minden, Hans A. Messner & Armand Keating. (2006) Flow cytometric assessment of autologous γδ T cells in patients with acute myeloid leukemia: Potential effector cells for immunotherapy?. Cytometry Part B: Clinical Cytometry 70B:6, pages 379-390.
Crossref
Hongwei WangFengdong ChengAlex CuencaPedro HornaZheng ZhengKapil BhallaEduardo M. Sotomayor. (2005) Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105:3, pages 1135-1143.
Crossref
Aaron A. Berlin & Nicholas W. Lukacs. (2005) Treatment of Cockroach Allergen Asthma Model with Imatinib Attenuates Airway Responses. American Journal of Respiratory and Critical Care Medicine 171:1, pages 35-39.
Crossref
T. YANAGI, D. SAWAMURA & H. SHIMIZU. (2004) Follicular mucinosis associated with imatinib (STI571). British Journal of Dermatology 151:6, pages 1276-1278.
Crossref
David E Spaner. (2004) Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. Journal of Leukocyte Biology 76:2, pages 338-351.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.